Advertisement
Screener

CRONOS GROUP INC. (CRON) Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

2.2 / 5 stars · 30/68 Roast Me

CRONOS GROUP INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

CRONOS GROUP INC. (CRON) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-02-26

  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $0.00.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $0.00.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $25.65M, a 9.85% increase from fiscal 2023.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $23.35M, a 61.97% decline from fiscal 2022.
  • CRONOS GROUP INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $61.39M.
Period endEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$0.00
10-K · filed 2026-02-26
2025-09-30$0.00
10-Q · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2025-11-06
$0.00
10-Q · filed 2025-11-06
$0.00
derived: sum of 4 quarters · filed 2026-02-26
2025-06-30$0.00
10-Q · filed 2025-08-07
$0.00
10-Q · filed 2025-08-07
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$0.00
derived: sum of 4 quarters · filed 2026-02-26
2025-03-31$0.00
10-Q · filed 2025-05-08
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$12.92M
derived: sum of 4 quarters · filed 2026-02-26
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$12.92M
derived: sum of 3 quarters · filed 2026-02-26
$25.65M
10-K · filed 2026-02-26
2024-09-30$0.00
10-Q · filed 2025-11-06
$12.92M
derived: sum of 2 quarters · filed 2025-11-06
$25.65M
10-Q · filed 2025-11-06
$49.00M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$12.92M
10-Q · filed 2025-08-07
$25.65M
10-Q · filed 2025-08-07
$49.00M
derived: sum of 3 quarters · filed 2026-02-26
$49.00M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$12.73M
10-Q · filed 2025-05-08
$36.08M
derived: sum of 2 quarters · filed 2026-02-26
$36.08M
derived: sum of 3 quarters · filed 2026-02-26
$36.08M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$23.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$23.35M
derived: sum of 2 quarters · filed 2026-02-26
$23.35M
derived: sum of 3 quarters · filed 2026-02-26
$23.35M
10-K · filed 2026-02-26
2023-09-30$0.00
10-Q · filed 2024-11-12
$0.00
derived: sum of 2 quarters · filed 2024-11-12
$0.00
10-Q · filed 2024-11-12
$21.18M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$0.00
10-Q · filed 2024-08-08
$0.00
10-Q · filed 2024-08-08
$21.18M
derived: sum of 3 quarters · filed 2025-02-27
$50.15M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$0.00
10-Q · filed 2024-05-09
$21.18M
derived: sum of 2 quarters · filed 2025-02-27
$50.15M
derived: sum of 3 quarters · filed 2025-02-27
$50.15M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$21.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$50.15M
derived: sum of 2 quarters · filed 2025-02-27
$50.15M
derived: sum of 3 quarters · filed 2025-02-27
$61.39M
10-K · filed 2025-02-27
2022-09-30$28.97M
10-Q · filed 2023-11-08
$28.97M
derived: sum of 2 quarters · filed 2023-11-08
$40.21M
10-Q · filed 2023-11-08
$40.21M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$0.00
10-Q · filed 2023-08-08
$11.24M
10-Q · filed 2023-08-08
$11.24M
derived: sum of 3 quarters · filed 2024-02-29
$11.24M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$11.24M
10-Q · filed 2023-05-09
$11.24M
derived: sum of 2 quarters · filed 2024-02-29
$11.24M
derived: sum of 3 quarters · filed 2024-02-29
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$0.00
derived: sum of 2 quarters · filed 2024-02-29
$0.00
10-K · filed 2024-02-29
2021-09-30$0.00
10-Q · filed 2022-11-07
$0.00
10-Q · filed 2022-11-07
2020-12-31$0.00
10-K · filed 2023-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87